Benefits of pre-surgical immunotherapy were independent of race in patients with aggressive breast cancer
Bottom Line: Treatment outcomes were similar between Black and non-Black patients with triple-negative breast cancer who received neoadjuvant durvalumab (Imfinzi) ...